Skip to main content

Table 4 Characteristics of included observational studies

From: Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults – a systematic review

Reference Type of study Aim Treatment Sample size and number of older participants Follow-up Outcomes
Burton 2006 [48] Regional cohort-study To measure the complication rates and adequacy of warfarin control in a cohort of patients with atrial fibrillation managed in primary care and to compare them with published data from controlled trials and community patients with atrial fibrillation not receiving warfarin. ASA, warfarin INR 2–3, no antithrombotic therapy N = 601, mean age 77 years. Subgroup analysis age ≥ 75 years. 5 years Antithrombotic treatment, stroke or TIA, bleeding complications, death
Sam 2004 [59] Community-based observational cohort-study To determine the prevalence of warfarin and ASA use in atrial fibrillation. ASA, warfarin, control N = 393, men: mean age 72.5 years, women: mean age 79 years. 14 years ASA and warfarin use, bleeding complication, cardiovascular events
  1. ASA acetylsalicylic acid, MI myocardial infarction, INR international normalized ratio, TIA transient ischaemic attack